Lithuanian CRISPR gene editing company Caszyme has added early-stage mRNA synthesis, analysis, and optimisation to its range of offerings.

The strategic development was announced at BIO2024 in San Diego, US.

Caszyme CEO Dr Monika Paulė comments: “The demand for tailored gene editing solutions continues to grow. By adding these new capabilities to test and optimise partners’ mRNA to our existing deep expertise in CRISPR gene editing technology, Caszyme will be able to offer more extensive development, validation and optimisation of early-stage therapeutic concepts. This advancement ensures high efficiency and precision in gene editing outcomes, fostering opportunities for deeper and more versatile partnerships.”

Caszyme was established in 2017 by Dr Monika Paulė together with Dr Giedrius Gasiūnas and Professor Virginijus Šikšnys, a pioneer of CRISPR-Cas gene editing research.

Over the last seven years, Caszyme has collaborated with multiple life science organisations aiming to enter the CRISPR field or expand their gene editing capabilities.

> Read an interview with Monika Paulė to find out more about the company.